The University of Illinois System Board of Trustees approved $232 million Thursday for UIC’s Drug Discovery and Cancer Research Pavilion, according to U of I System News. The vote authorizes the project to move toward procurement and construction at 1725 West Polk Street in the Illinois Medical District.
The state procurement record describes an approximately 190,000-square-foot, multistory building on UIC’s west campus. Planned north of the University of Illinois Hospital, it would connect directly to the existing Pharmacy Building and sit beside the Polk Street Pink Line station. The Illinois Capital Development Board document lists laboratories, instrumentation rooms, classrooms, conference rooms and offices for drug-discovery research and collaboration among university units.
A research facility with an equity mission
UIC says the pavilion will bring together researchers from the University of Illinois Cancer Center, the Retzky College of Pharmacy and the Department of Chemistry. The state project description connects the co-location of cancer-research programs with UIC’s effort to pursue National Cancer Institute designation, which could bring federal recognition and additional funding opportunities.
Health equity is a central rationale for the project. On its pavilion website, UIC says a Black woman in Chicago’s Englewood neighborhood is 40% more likely to die from breast cancer than a white woman in Streeterville. Chicago YIMBY has also reported that the university hopes to increase minority participation in clinical trials from about 10% to roughly 40%; that target remains attributed to the outlet rather than presented as independently verified here.
Broader health and district context
Statewide figures show the scale of the disease burden behind the pavilion’s cancer-research focus. Illinois reported 10,981 women and 117 men diagnosed with breast cancer and 1,697 women and 23 men who died from it in 2021, according to the Illinois Department of Public Health. Those figures provide statewide context but do not themselves measure the neighborhood-level difference cited by UIC. The project also aligns with the Illinois Medical District’s broader planning goals. Its FY2025–2026 strategic plan positions the district as a center for patient care, medical research and inclusive economic growth, emphasizing collaboration, innovation and community, according to the Illinois Medical District Commission.
Funding and institutional support
The project’s financing is expected to combine UIC operating funds, private gifts and state appropriations, although the final share from each source and the construction timetable have not been established publicly. UIC alumnus Herb Paaren gave $2 million in 2025 for pavilion construction and drug-discovery expansion, according to UIC. Carol Retzky committed another $2 million in 2019 as the leading private gift for the planned facility, according to the UIC Retzky College of Pharmacy.
The college adopted the Retzky name in September 2024 after receiving a $36 million estate gift from Herbert and Carol Retzky, making it UIC’s first donor-named college, according to the pharmacy school. Their earlier support and the new pavilion are part of the university’s broader effort to expand pharmacy, drug-discovery and cancer research.
The board’s vote establishes the project’s current status: UIC has approval to advance the dedicated research facility into procurement and construction. The final shares of operating funds, private gifts and state appropriations, as well as the construction timetable, have not been established publicly.
